Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2009
08/13/2009WO2009062746A3 Topical drugs for use in antifungal therapy
08/13/2009WO2009062132A3 Immunomodulating compounds and related compositions and methods
08/13/2009WO2009062084A3 Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery
08/13/2009WO2009060281A3 Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
08/13/2009WO2009058815A3 Lipoxin a4 protection for retinal cells
08/13/2009WO2009056754A3 Use of econazole or salts thereof for treating acne
08/13/2009WO2009056737A3 Novel nacl salt substitute, use thereof and products containing same
08/13/2009WO2009053446A3 Pregabalin intermediates and process for preparing them and pregabalin
08/13/2009WO2009052972A3 Use of norgestimate as a selective inhibitor of trpc3, trpc6 and trpc7 ion channels
08/13/2009WO2009052073A3 Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
08/13/2009WO2009051660A3 Compounds for activating tgf-beta signaling
08/13/2009WO2009050201A3 4-phenyl-5-oxo-imidazole derivatives, pharmaceutical compositions and uses therof
08/13/2009WO2009047800A3 Oral controlled release composition of carvedilol
08/13/2009WO2009046444A3 Formulation for intranasal administration of diazepam
08/13/2009WO2009045535A3 Fluorine-18 derivative of dasatinib and uses thereof
08/13/2009WO2009041705A9 5-membered heterocyclic compounds as proton pump inhibitors
08/13/2009WO2009037538A3 Process for the preparation of lamivudine form i
08/13/2009WO2009036933A3 Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles
08/13/2009WO2009034475A3 Perharidines as cdk inhibitors
08/13/2009WO2009033770A3 Calcitonin c-terminal flanking peptide for use as a therapeutic agent
08/13/2009WO2009032754A3 Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
08/13/2009WO2009030224A3 Novel quinazoline compounds and the use thereof for treating cancerous diseases
08/13/2009WO2009027056A3 Antioxidant and paramagnetic heparin-nitroxide derivatives
08/13/2009WO2009020683A3 Quinazoline compounds
08/13/2009WO2009019662A3 Oral metaxalone compositions
08/13/2009WO2009019294A3 Bupropion hydrobromide and therapeutic applications
08/13/2009WO2009017855A3 Aneurysm occlusion device containing bioactive and biocompatible copolymer shell and a liquid embolic agent and a biocompatible metallic frame member
08/13/2009WO2009013594A3 Process for the preparation of controlled-release solid formulations containing oxcarbazepine, and formulations obtainable by said process
08/13/2009WO2009007749A3 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
08/13/2009WO2009003719A3 Indane-amine derivatives, their preparation and use as medicaments
08/13/2009WO2008145281A3 Formulations containing triazinones and iron
08/13/2009WO2008143880A8 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
08/13/2009WO2008140507A8 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
08/13/2009WO2008129396A3 Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
08/13/2009WO2008121028A3 Use of 9-oxoacridine-10-acetic acid, salts and esters thereof in combination therapy of ovarian cancer
08/13/2009WO2008108958A8 Benzimidazole derivatives and methods of use thereof
08/13/2009WO2008104956A3 Process for the preparation of amorphous cabergoline
08/13/2009WO2008098364A8 Reducing post-operative adhesion formation with intraperitoneal glutamine
08/13/2009WO2008080268A8 Derivates of substituted tartaric aicd and usage for preparating beta secretase inhibitors
08/13/2009WO2008064132A3 Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
08/13/2009WO2008035229A3 Compositions and methods for ph targeted drug delivery
08/13/2009WO2008031104A3 Antimicrobial compositions and related applications
08/13/2009WO2005122682A3 Process for the preparation of esters of piperazic acid
08/13/2009US20090205062 Caspase-9 deficient animals and the use thereof
08/13/2009US20090204489 Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
08/13/2009US20090204204 Drug/Drug Deliver Systems For The Prevention And Treatment Of Vascular Disease
08/13/2009US20090203906 4-[((4-carboxybutyl){2-[2-({4-[2-(4-hydroxyphenyl)ethyl]benzyl}oxy)phenyl]-ethyl}amino)methyl]benzoic acid, which stimulate soluble guanylate cyclase via a novel mechanism of action, used for the treatment of cardiovascular disorders and fibrotic disorders
08/13/2009US20090203896 Modulation of survivin expression
08/13/2009US20090203894 Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
08/13/2009US20090203892 Retrotransposon Inhibition in Therapy
08/13/2009US20090203890 Hepatitis c antivirals
08/13/2009US20090203803 N-acylated chitinous polymers and methods of use thereof
08/13/2009US20090203800 Cytostatic Composition
08/13/2009US20090203799 Novel compositions comprising carotenoids
08/13/2009US20090203798 Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar Alcohol
08/13/2009US20090203797 Antimycotic Patch
08/13/2009US20090203796 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
08/13/2009US20090203794 Aqueous Anaesthetic Composition Comprising Propofol
08/13/2009US20090203793 Compounds for the treatment of metabolic disorders
08/13/2009US20090203792 Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators
08/13/2009US20090203791 Nateglinide-containing preparation
08/13/2009US20090203790 Gamma-l-pga producing microorganism, method of producing gamma-l-pga using the microorganism, crosslinked substance produced using the microorganism, and external dermal agent produced using the microorganism
08/13/2009US20090203789 Fast Dissolution Amino Acid Composition
08/13/2009US20090203788 Method of enhancing reproductive function of mammals by feeding of conjugated linoleic acids
08/13/2009US20090203787 Very long chain polyunsaturated fatty acids, methods of production, and uses
08/13/2009US20090203786 Methods and Composition for Improving Cognitive Function
08/13/2009US20090203785 Method and process for producing youthful-appearing, small-pored, and smooth skin
08/13/2009US20090203784 Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors
08/13/2009US20090203783 Therapeutic agent for acute cerebral infarct
08/13/2009US20090203782 Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders
08/13/2009US20090203781 N-N-Acyloxypropyl Lysine Methyl Ester-and N,N-Bis(N-Acyloxypropyl) Lysine Methyl Ester-Type Compounds and Use Thereof as Surface-Active Agents with an Antimicrobial Activity
08/13/2009US20090203780 Use of a Polyunsaturated Fatty Acid Compound
08/13/2009US20090203779 Esters of long-chain alcohols and preparation thereof
08/13/2009US20090203778 Fatty acid analogues, i.e. including dha derivatives for uses as a medicament
08/13/2009US20090203777 Organic compounds
08/13/2009US20090203776 Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects
08/13/2009US20090203775 Novel compound and a novel microorganism for producing the novel compound
08/13/2009US20090203774 Substituted benzyl ester derivative and use thereof
08/13/2009US20090203773 Compounds for the Treatment of Non-Autoimmune Type 2 Diabetes Mellitus and/or Syndrome X
08/13/2009US20090203772 Vaginal Health Products
08/13/2009US20090203771 Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
08/13/2009US20090203770 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS
08/13/2009US20090203768 Nucleic acid-containing complex
08/13/2009US20090203767 Inhibition stat-1
08/13/2009US20090203766 vWF aptamer formulations and methods for use
08/13/2009US20090203765 Modulation of eif4e-bp2 expression
08/13/2009US20090203764 Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
08/13/2009US20090203763 Substituted benzhydrylethers
08/13/2009US20090203762 Methods for the production of biliverdin
08/13/2009US20090203761 Process for preparing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives
08/13/2009US20090203759 Pharmaceutical formulation of nitrooxyderivatives of nsaids
08/13/2009US20090203758 angiotensin converting enzyme inhibitors, used for the treatment of congestive heart failure aand as hypotensive agents; dissolving perindopril and L-arginine in water, adding apolar and polar solvents, then filtering, washing and drying the crystals obtained
08/13/2009US20090203757 Ethylene glycol esters as photoactive agents
08/13/2009US20090203755 Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
08/13/2009US20090203754 Anti-bacterial drug targeting of genome maintenance interfaces
08/13/2009US20090203753 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists
08/13/2009US20090203752 Compounds for nonsense suppression, and methods for their use
08/13/2009US20090203751 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
08/13/2009US20090203750 5-HT2C Receptor Agonists as Anorectic Agents
08/13/2009US20090203749 Agent for control of degranulation reaction and cytokine production